Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface, Cornea / Ocular Surface

Minimally Invasive, Maximally Successful

Corneal anesthesia is a debilitating condition in which the function of the ophthalmic division of the trigeminal nerve is impaired and the brain receives little or no pain sensation from the cornea. This loss of sensation, which may be congenital or secondary to a variety of causes, means that, over time, minor corneal injuries add up to significant ulceration, scarring, and ultimately blindness. Not only that, but corneal sensation is critical for limbal stem cell function, so its absence impairs repair of the corneal epithelium. Most treatment options – artificial tears, corneal or scleral contact lenses, and in more severe cases, tarsorrhaphy and keratoplasty – can help, but all fail to address the underlying problem.

All is not completely lost, though. There is a type of surgery that can address the root cause (1): corneal neurotization with locally available donor nerves (typically the supraorbital and supratrochlear nerves). But this has historically been a rather invasive approach – initial procedures took 10 hours to perform and required an incision from ear to ear across the forehead, extensive dissection, and the denervation of the contralateral forehead and scalp. But now, a team of Toronto-based surgeons have refined the procedure into a minimally invasive approach that uses a sural nerve graft from the leg (2,3). The new operation requires only a small upper lid incision to access the supratrochlear nerve for neurotization and the creation of a subcutaneous tunnel along the nasal bridge to connect the supratrochlear nerve to the globe. But crucially, it spares the supraorbital nerve – and with it, forehead sensation – and results in minimal scarring.

What happens to the patients after surgery? The team believe that the graft slowly innervates the cornea at around one millimeter per day, with sensation typically returning within six months. Those with damaged corneal epithelia might experience pain postoperatively, but once protective sensation is established, the discomfort subsides as the ocular surface is allowed to heal. Of note, patients initially reported that mechanical stimulation of the cornea felt like the cutaneous skin territory of the supratrochlear nerve was being stimulated. But over the few months following surgery, patients shifted to perceiving this as true corneal sensation – suggesting that some degree of central nervous system remodeling takes place (3). The first patient to receive the treatment experienced significant improvements in corneal clarity, and is now eligible for a corneal transplant. Of the four children and one adult who have undergone this procedure, all have experienced the development of a protective corneal sensation by six months postsurgery, and to date, follow-up has uncovered no ocular healing problems or loss of forehead sensation.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. JK Terzis, et al., “Corneal neurotization: a novel solution to neurotrophic keratopathy”, Plast Reconstr Surg, 123, 112–120 (2009). PMID: 19116544.
  2. U Elbaz, et al., “Restoration of corneal sensation with regional nerve transfers and nerve grafts: a new approach to a difficult problem”, JAMA Ophthalmol, 132, 1289–1295 (2014). PMID: 25010775.
  3. RD Bains, et al., “Corneal neurotization from the supratrochlear nerve with sural nerve grafts: a minimally invasive approach”, Plast Reconstr Surg, 135, 397e–400e (2015). PMID: 25626824.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register